Overview of role of survivin in cancer: expression, regulation, functions, and its potential as a therapeutic target

References

• Albadari N, Li W. Survivin small molecules inhibitors: recent advances and challenges. Molecules. 2023;28(3):1376. doi: 10.3390/molecules28031376.
   PubMed Web of Science ®Google Scholar
• Rafatmanesh A, Behjati M, Mobasseri N, et al. The survivin molecule as a double-edged sword in cellular physiologic and pathologic conditions and its role as a potential biomarker and therapeutic target in cancer. J Cell Physiol. 2019;235(2):725–744. doi: 10.1002/jcp.29027.
   PubMed Web of Science ®Google Scholar
• Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. 1997;3(8):917–921. doi: 10.1038/nm0897-917.
   PubMed Web of Science ®Google Scholar
• Deveraux QL, Reed JC. IAP family proteins–suppressors of apoptosis. Genes Dev. 1999;13(3):239–252. doi: 10.1101/gad.13.3.239.
   PubMed Web of Science ®Google Scholar
• Tamm I, Wang Y, Sausville E, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by fas (CD95), bax, caspases, and anticancer drugs. Cancer Res. 1998;58(23):5315–5320.
   PubMed Web of Science ®Google Scholar
• Jafarzadeh A, Bazargan N, Chatrabnous N, et al. Contribution of survivin to the immune system, allergies and autoimmune diseases. Hum Immunol. 2023;84(4):301–310. doi: 10.1016/j.humimm.2023.01.009.
   PubMed Web of Science ®Google Scholar
• Fernández JG, Rodríguez DA, Valenzuela M, et al. Survivin expression promotes VEGF-induced tumor angiogenesis via PI3K/akt enhanced beta-catenin/Tcf-Lef dependent transcription. Mol Cancer. 2014;13(1):209. doi: 10.1186/1476-4598-13-209.
   PubMedGoogle Scholar
• Li Z, Ren W, Zeng Q, et al. Effects of survivin on angiogenesis in vivo and in vitro. Am J Transl Res. 2016;8(2):270–283.
   PubMed Web of Science ®Google Scholar
• Wang Q, Chen Z, Diao X, et al. Induction of autophagy-dependent apoptosis by the survivin suppressant YM155 in prostate cancer cells. Cancer Lett. 2011;302(1):29–36. doi: 10.1016/j.canlet.2010.12.007.
   PubMed Web of Science ®Google Scholar
• Fukuda S, Abe M, Onishi C, et al. Survivin selectively modulates genes deregulated in human leukemia stem cells. J Oncol. 2011;2011:946936. doi: 10.1155/2011/946936.
   PubMedGoogle Scholar
• Bernardo PS, Lemos LGT, de Moraes GN, et al. Unraveling survivin expression in chronic myeloid leukemia: molecular interactions and clinical implications. Blood Rev. 2020;43:100671. doi: 10.1016/j.blre.2020.100671.
   PubMed Web of Science ®Google Scholar
• Warrier NM, Agarwal P, Kumar P. Emerging importance of survivin in stem cells and cancer: the development of new cancer therapeutics. Stem Cell Rev Rep. 2020;16(5):828–852. doi: 10.1007/s12015-020-09995-4.
   PubMed Web of Science ®Google Scholar
• Martínez-Sifuentes MA, Bassol-Mayagoitia S, Nava-Hernández MP, et al. Survivin in breast cancer: a review. Genet Test Mol Biomarkers. 2022;26(9):411–421. 2022/09/01 doi: 10.1089/gtmb.2021.0286.
   PubMed Web of Science ®Google Scholar
• Li F, Altieri DC. Transcriptional analysis of human survivin gene expression. Biochem J. 1999;344(Pt 2):305–311. doi: 10.1042/0264-6021:3440305.
   PubMedGoogle Scholar
• Lyu H, Huang J, He Z, et al. Epigenetic mechanism of survivin dysregulation in human cancer. Sci China Life Sci. 2018;61(7):808–814. doi: 10.1007/s11427-017-9230-2.
   PubMed Web of Science ®Google Scholar
• Mityaev MV, Kopantzev EP, Buzdin AA, et al. Functional significance of a putative sp1 transcription factor binding site in the survivin gene promoter. Biochemistry. 2008;73(11):1183–1191.
   PubMed Web of Science ®Google Scholar
• Chang HL, Chen CY, Hsu YF, et al. Simvastatin induced HCT116 colorectal cancer cell apoptosis through p38MAPK-p53-survivin signaling Cascade. Biochim Biophys Acta. 2013;1830(8):4053–4064. doi: 10.1016/j.bbagen.2013.04.011.
   PubMed Web of Science ®Google Scholar
• Zhou M, Gu L, Li F, et al. DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells. J Pharmacol Exp Ther. 2002;303(1):124–131. doi: 10.1124/jpet.102.037192.
   PubMed Web of Science ®Google Scholar
• Nakano J, Huang CL, Liu DG, et al. Survivin gene expression is negatively regulated by the p53 tumor suppressor gene in non-small cell lung cancer. Int J Oncol. 2005;27(5):1215–1221. doi: 10.3892/ijo.27.5.1215.
   PubMed Web of Science ®Google Scholar
• Estève P-O, Chin HG, Pradhan S. Molecular mechanisms of transactivation and doxorubicin-mediated repression of survivin gene in cancer cells. J Biol Chem. 2007;282(4):2615–2625. doi: 10.1074/jbc.M606203200.
   PubMed Web of Science ®Google Scholar
• Smallwood A, Estève P-O, Pradhan S, et al. Functional cooperation between HP1 and DNMT1 mediates gene silencing. Genes Dev. 2007;21(10):1169–1178. doi: 10.1101/gad.1536807.
   PubMed Web of Science ®Google Scholar
• Papanikolaou V, Iliopoulos D, Dimou I, et al. Survivin regulation by HER2 through NF-kappaB and c-myc in irradiated breast cancer cells. J Cell Mol Med. 2011;15(7):1542–1550. doi: 10.1111/j.1582-4934.2010.01149.x.
   PubMed Web of Science ®Google Scholar
• Zhu ZB, Makhija SK, Lu B, et al. Transcriptional targeting of tumors with a novel tumor-specific survivin promoter. Cancer Gene Ther. 2004;11(4):256–262. doi: 10.1038/sj.cgt.7700679.
   PubMed Web of Science ®Google Scholar
• Yang L, Cao Z, Li F, et al. Tumor-specific gene expression using the survivin promoter is further increased by hypoxia. Gene Ther. 2004;11(15):1215–1223. doi: 10.1038/sj.gt.3302280.
   PubMed Web of Science ®Google Scholar
• Dohi T, Xia F, Altieri DC. Compartmentalized phosphorylation of IAP by protein kinase a regulates cytoprotection. Mol Cell. 2007;27(1):17–28. doi: 10.1016/j.molcel.2007.06.004.
   PubMed Web of Science ®Google Scholar
• Wheatley SP, Barrett RM, Andrews PD, et al. Phosphorylation by Aurora-B negatively regulates survivin function during mitosis. Cell Cycle. 2007;6(10):1220–1230. doi: 10.4161/cc.6.10.4179.
   PubMed Web of Science ®Google Scholar
• Nogueira-Ferreira R, Vitorino R, Ferreira-Pinto MJ, et al. Exploring the role of post-translational modifications on protein-protein interactions with survivin. Arch Biochem Biophys. 2013;538(2):64–70. doi: 10.1016/j.abb.2013.07.027.
   PubMed Web of Science ®Google Scholar
• Garg H, Suri P, Gupta J, et al. Survivin: a unique target for tumor therapy. Cancer Cell Int. 2016;16(1):49. doi: 10.1186/s12935-016-0326-1.
   PubMedGoogle Scholar
• Wheatley S, Altieri D. Survivin at a glance. J Cell Sci. 2019;132(7). doi: 10.1242/jcs.223826.
   Web of Science ®Google Scholar
• Zhao J, Tenev T, Martins LM, et al. The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J Cell Sci. 2000;113 Pt 23:4363–4371. doi: 10.1242/jcs.113.23.4363.
   PubMed Web of Science ®Google Scholar
• Chen H, Yang F, Li X, et al. Long noncoding RNA LNC473 inhibits the ubiquitination of survivin via association with USP9X and enhances cell proliferation and invasion in hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2018;499(3):702–710. doi: 10.1016/j.bbrc.2018.03.215.
   PubMed Web of Science ®Google Scholar
• Hindorff LA, Sethupathy P, Junkins HA, et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci USA. 2009 2009;106(23):9362–9367. doi: 10.1073/pnas.0903103106.
   PubMed Web of Science ®Google Scholar
• Manolio TA, Collins FS, Cox NJ, et al. Finding the missing heritability of complex diseases. Nature. 2009;461(7265):747–753. doi: 10.1038/nature08494.
   PubMed Web of Science ®Google Scholar
• Gunaldi M, Isiksacan N, Kocoglu H, et al. The value of serum survivin level in early diagnosis of cancer. J Cancer Res Ther. 2018;14(3):570–573.
   PubMed Web of Science ®Google Scholar
• Wang YH, Chiou HY, Lin CT, et al. Association between survivin gene promoter-31 C/G polymorphism and urothelial carcinoma risk in Taiwanese population. Urology. 2009;73(3):670–674. doi: 10.1016/j.urology.2008.09.048.
   PubMed Web of Science ®Google Scholar
• Jaiswal PK, Goel A, Mandhani A, et al. Functional polymorphisms in promoter survivin gene and its association with susceptibility to bladder cancer in North indian cohort. Mol Biol Rep. 2012;39(5):5615–5621. doi: 10.1007/s11033-011-1366-1.
   PubMed Web of Science ®Google Scholar
• Yamak N, Yaykasli KO, Yilmaz U, et al. Association between survivin gene polymorphisms and the susceptibility to colon cancer development in the Turkish population. Asian Pac J Cancer Prev. 2014;15(20):8963–8967. doi: 10.7314/apjcp.2014.15.20.8963.
   PubMedGoogle Scholar
• Gazouli M, Tzanakis N, Rallis G, et al. Survivin -31G/C promoter polymorphism and sporadic colorectal cancer. Int J Colorectal Dis. 2009;24(2):145–150. doi: 10.1007/s00384-008-0601-2.
   PubMed Web of Science ®Google Scholar
• Zahedi P, Aminimoghaddam S, Sayahpour FA, et al. Association of survivin gene polymorphism with endometrial cancer. Int J Gynecol Cancer. 2012;22(1):35–37. doi: 10.1097/IGC.0b013e318229902c.
   PubMed Web of Science ®Google Scholar
• Upadhyay R, Khurana R, Kumar S, et al. Role of survivin gene promoter polymorphism (-31G > C) in susceptibility and survival of esophageal cancer in Northern India. Ann Surg Oncol. 2011;18(3):880–887. doi: 10.1245/s10434-010-1371-y.
   PubMed Web of Science ®Google Scholar
• Theodoropoulos GE, Michalopoulos NV, Panoussopoulos SG, et al. Effects of caspase-9 and survivin gene polymorphisms in pancreatic cancer risk and tumor characteristics. Pancreas. 2010;39(7):976–980. doi: 10.1097/MPA.0b013e3181d705d4.
   PubMed Web of Science ®Google Scholar
• Rasool I, Afroze D, Wani KA, et al. Role of the functional polymorphism of survivin gene-31G/C) and risk of breast cancer in a North Indian population. Clin Breast Cancer. 2018;18(4):E671–E676. doi: 10.1016/j.clbc.2017.11.011.
   PubMed Web of Science ®Google Scholar
• Qin C, Cao Q, Li P, et al. Functional promoter-31G > C variant in survivin gene is associated with risk and progression of renal cell cancer in a Chinese population. PLOS One. 2012;7(1):e28829. doi: 10.1371/journal.pone.0028829.
   PubMed Web of Science ®Google Scholar
• Xu Y, Fang F, Ludewig G, et al. A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol. 2004;23(7):419–429. doi: 10.1089/1044549041474788.
   PubMed Web of Science ®Google Scholar
• Bogdanovic L, Lazic M, Bogdanovic J, et al. Polymorphisms of survivin-31 G/C gene are associated with risk of urothelial carcinoma in Serbian population. J Buon. 2017;22(1):270–277.
   PubMed Web of Science ®Google Scholar
• Weng CJ, Hsieh YH, Chen MK, et al. Survivin SNP-carcinogen interactions in oral cancer. J Dent Res. 2012;91(4):358–363. doi: 10.1177/0022034512438402.
   PubMed Web of Science ®Google Scholar
• Kostic M, Nikolic N, Ilic B, et al. Analysis of polymorphism in the survivin gene promoter as a potential risk factor for head and neck cancers development. Srp Arh Celok Lek. 2013;141(5–6):304–307. doi: 10.2298/SARH1306304K.
   PubMed Web of Science ®Google Scholar
• Bayram S, Akkız H, Bekar A, et al. The association between the survivin-31G/C promoter polymorphism and hepatocellular carcinoma risk in a Turkish population. Cancer Epidemiol. 2011;35(6):555–559. doi: 10.1016/j.canep.2011.01.004.
   PubMed Web of Science ®Google Scholar
• Karimian M, Aftabi Y, Mazoochi T, et al. Survivin polymorphisms and susceptibility to prostate cancer: a genetic association study and an in silico analysis. Excli J. 2018;17:479–491.
   PubMed Web of Science ®Google Scholar
• Yang X, Xiong G, Chen X, et al. Polymorphisms of survivin promoter are associated with risk of esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2009;135(10):1341–1349. doi: 10.1007/s00432-009-0575-7.
   PubMed Web of Science ®Google Scholar
• Hsieh YS, Tsai CM, Yeh CB, et al. Survivin T9809C, an SNP located in 3′-UTR, displays a correlation with the risk and clinicopathological development of hepatocellular carcinoma. Ann Surg Oncol. 2012;19(S3):S625–S633. doi: 10.1245/s10434-011-2123-3.
   PubMedGoogle Scholar
• Zhou T, Li H-Y, Xie W-J, et al. Association of glutathione S-transferase gene polymorphism with bladder cancer susceptibility. BMC Cancer. 2018;18(1):1088. doi: 10.1186/s12885-018-5014-1.
   PubMedGoogle Scholar
• McWilliams RR, Bamlet WR, Cunningham JM, et al. Polymorphisms in DNA repair genes, smoking, and pancreatic adenocarcinoma risk. Cancer Res. 2008;68(12):4928–4935. doi: 10.1158/0008-5472.CAN-07-5539.
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–297. doi: 10.1016/s0092-8674(04)00045-5.
   PubMed Web of Science ®Google Scholar
• Hirata H, Ueno K, Shahryari V, et al. MicroRNA-182-5p promotes cell invasion and proliferation by down regulating FOXF2, RECK and MTSS1 genes in human prostate cancer. PLOS One. 2013;8(1):e55502. doi: 10.1371/journal.pone.0055502.
   PubMed Web of Science ®Google Scholar
• Li Y, Chen S, Shan Z, et al. miR-182-5p improves the viability, mitosis, migration, and invasion ability of human gastric cancer cells by down-regulating RAB27A. Biosci Rep. 2017;37(3):BSR20170136. doi: 10.1042/BSR20170136.
   PubMedGoogle Scholar
• Wu X, Dai L, Zhang Z, et al. Overexpression of microRNA-203 can downregulate survivin and function as a potential therapeutic target in papillary thyroid cancer. Oncol Lett. 2020;19(1):61–68.
   PubMed Web of Science ®Google Scholar
• Wang S, Zhu L, Zuo W, et al. MicroRNA-mediated epigenetic targeting of survivin significantly enhances the antitumor activity of paclitaxel against non-small cell lung cancer. Oncotarget. 2016;7(25):37693–37713. doi: 10.18632/oncotarget.9264.
   PubMedGoogle Scholar
• Saini S, Majid S, Yamamura S, et al. Regulatory role of mir-203 in prostate cancer progression and metastasis. Clin Cancer Res. 2011;17(16):5287–5298. doi: 10.1158/1078-0432.CCR-10-2619.
   PubMed Web of Science ®Google Scholar
• Xu D, Wang Q, An Y, et al. MiR‑203 regulates the proliferation, apoptosis and cell cycle progression of pancreatic cancer cells by targeting survivin. Mol Med Rep. 2013;8(2):379–384. doi: 10.3892/mmr.2013.1504.
   PubMed Web of Science ®Google Scholar
• Kapadia C, Ioele S, Day E. Layer-by-layer assembled PLGA nanoparticles carrying miR-34a cargo inhibit the proliferation and cell cycle progression of triple-negative breast cancer cells. J Biomed Mater Res A. 2020;108(3):601–613. doi: 10.1002/jbm.a.36840.
   PubMed Web of Science ®Google Scholar
• Kumar B, Yadav A, Lang J, et al. Dysregulation of microRNA-34a expression in head and neck squamous cell carcinoma promotes tumor growth and tumor angiogenesis. PLOS One. 2012;7(5):e37601. doi: 10.1371/journal.pone.0037601.
   PubMed Web of Science ®Google Scholar
• Cao W, Fan R, Wang L, et al. Expression and regulatory function of miRNA-34a in targeting survivin in gastric cancer cells. Tumour Biol. 2013;34(2):963–971. doi: 10.1007/s13277-012-0632-8.
   PubMedGoogle Scholar
• Sato K, Osaka E, Fujiwara K, et al. miRNA‑218 targets multiple oncogenes and is a therapeutic target for osteosarcoma. Oncol Rep. 2022;47(5):92. doi: 10.3892/or.2022.8303.
   Web of Science ®Google Scholar
• Yu M, Xu B, Yang H, et al. MicroRNA-218 regulates the chemo-sensitivity of cervical cancer cells through targeting survivin. Cancer Manag Res. 2019;11:6511–6519. doi: 10.2147/CMAR.S199659.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Kong Y, Yang W, et al. MicroRNA-218 enhances gastric cancer cell cisplatin sensitivity by targeting survivin. Exp Ther Med. 2018;16(6):4796–4802. doi: 10.3892/etm.2018.6802.
   PubMed Web of Science ®Google Scholar
• Ou D, Wu Y, Liu J, et al. miRNA-335 and miRNA-182 affect the occurrence of tongue squamous cell carcinoma by targeting survivin. Oncol Lett. 2016;12(4):2531–2537. doi: 10.3892/ol.2016.4938.
   PubMed Web of Science ®Google Scholar
• Subramanian C, McCallister R, Cohen M. Multi-genomic analysis of 260 adrenocortical cancer patient tumors identifies novel network BIRC5-hsa-miR-335-5p-PAX8-AS1 strongly associated with poor survival. Surgery. 2023;173(1):43–51. doi: 10.1016/j.surg.2022.08.025.
   PubMed Web of Science ®Google Scholar
• Yun S, Kim WK, Kwon Y, et al. Survivin is a novel transcription regulator of KIT and is downregulated by miRNA-494 in gastrointestinal stromal tumors. Int J Cancer. 2018;142(10):2080–2093. doi: 10.1002/ijc.31235.
   PubMed Web of Science ®Google Scholar
• Xu S, Li D, Li T, et al. miR-494 sensitizes gastric cancer cells to TRAIL treatment through downregulation of survivin. Cell Physiol Biochem. 2018;51(5):2212–2223. doi: 10.1159/000495867.
   PubMedGoogle Scholar
• Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature. 2007;449(7163):682–688. doi: 10.1038/nature06174.
   PubMed Web of Science ®Google Scholar
• Grimaldi AM, Salvatore M, Incoronato M. miRNA-based therapeutics in breast cancer: a systematic review. Front Oncol. 2021;11:668464. doi: 10.3389/fonc.2021.668464.
   PubMedGoogle Scholar
• Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer. 2008;8(1):61–70. doi: 10.1038/nrc2293.
   PubMed Web of Science ®Google Scholar
• Pu F, Shao Z, Yang S, et al. Association between functional variants in BIRC5/survivin gene 3′ untranslated region and mRNA expression in lymphoblastoid cell lines. Oncol Lett. 2015;10(4):2319–2322. doi: 10.3892/ol.2015.3507.
   PubMed Web of Science ®Google Scholar
• Végran F, Mary R, Gibeaud A, et al. Survivin-3B potentiates immune escape in cancer but also inhibits the toxicity of cancer chemotherapy. Cancer Res. 2013;73(17):5391–5401. doi: 10.1158/0008-5472.CAN-13-0036.
   PubMed Web of Science ®Google Scholar
• Ebrahimiyan H, Aslani S, Rezaei N, et al. Survivin and autoimmunity; the ins and outs. Immunol Lett. 2018;193:14–24. doi: 10.1016/j.imlet.2017.11.004.
   PubMed Web of Science ®Google Scholar
• Adamopoulos P, Tsiakanikas P, Adam E, et al. Unraveling novel survivin mRNA transcripts in cancer cells using an in-house developed targeted high-throughput sequencing approach. Genomics. 2021;113(1 Pt 2):573–581. doi: 10.1016/j.ygeno.2020.09.053.
   PubMed Web of Science ®Google Scholar
• Necochea-Campion R, Chen C, Mirshahidi S, et al. Clinico-pathologic relevance of survivin splice variant expression in cancer. Cancer Lett. 2013;339(2):167–174. doi: 10.1016/j.canlet.2013.06.007.
   PubMed Web of Science ®Google Scholar
• Kavurma M, Santiago F, Bonfoco E, et al. Sp1 phosphorylation regulates apoptosis via extracellular FasL-Fas engagement. J Biol Chem. 2001;276(7):4964–4971. doi: 10.1074/jbc.M009251200.
   PubMed Web of Science ®Google Scholar
• Kolenko VM, Uzzo RG, Bukowski R, et al. Caspase-dependent and -independent death pathways in cancer therapy. Apoptosis. 2000;5(1):17–20. doi: 10.1023/a:1009677307458.
   PubMed Web of Science ®Google Scholar
• Park M, Kim S, Kim Y, et al. ALS2CR7 (CDK15) attenuates TRAIL induced apoptosis by inducing phosphorylation of survivin Thr34. Biochem Biophys Res Commun. 2014;450(1):129–134. doi: 10.1016/j.bbrc.2014.05.070.
   PubMed Web of Science ®Google Scholar
• Marusawa H, Matsuzawa S, Welsh K, et al. HBXIP functions as a cofactor of survivin in apoptosis suppression. EMBO J. 2003;22(11):2729–2740. doi: 10.1093/emboj/cdg263.
   PubMed Web of Science ®Google Scholar
• Song Z, Yao X, Wu M. Direct interaction between survivin and smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J Biol Chem. 2003;278(25):23130–23140. doi: 10.1074/jbc.M300957200.
   PubMed Web of Science ®Google Scholar
• Jaiswal P, Goel A, Mittal R. Survivin: a molecular biomarker in cancer. Indian J Med Res. 2015;141(4):389–397. doi: 10.4103/0971-5916.159250.
   PubMed Web of Science ®Google Scholar
• Dohi T, Beltrami E, Wall N, et al. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest. 2004;114(8):1117–1127. doi: 10.1172/JCI200422222.
   PubMed Web of Science ®Google Scholar
• O'Connor D, Grossman D, Plescia J, et al. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci USA. 2000;97(24):13103–13107. doi: 10.1073/pnas.240390697.
   PubMed Web of Science ®Google Scholar
• Riedl SJ, Renatus M, Schwarzenbacher R, et al. Structural basis for the inhibition of caspase-3 by XIAP. Cell. 2001;104(5):791–800. doi: 10.1016/s0092-8674(01)00274-4.
   PubMed Web of Science ®Google Scholar
• Altieri DC. Survivin and IAP proteins in cell-death mechanisms. Biochem J. 2010;430(2):199–205. doi: 10.1042/BJ20100814.
   PubMedGoogle Scholar
• Zumbrägel FK, Machtens DA, Curth U, et al. Survivin does not influence the anti-apoptotic action of XIAP on caspase-9. Biochem Biophys Res Commun. 2017;482(4):530–535. doi: 10.1016/j.bbrc.2016.11.094.
   PubMed Web of Science ®Google Scholar
• Niu TK, Cheng Y, Ren X, et al. Interaction of beclin 1 with survivin regulates sensitivity of human glioma cells to TRAIL-induced apoptosis. FEBS Lett. 2010;584(16):3519–3524. doi: 10.1016/j.febslet.2010.07.018.
   PubMed Web of Science ®Google Scholar
• Hay-Koren A, Bialik S, Levin-Salomon V, et al. Changes in cIAP2, survivin and BimEL expression characterize the switch from autophagy to apoptosis in prolonged starvation. J Intern Med. 2017;281(5):458–470. doi: 10.1111/joim.12616.
   PubMed Web of Science ®Google Scholar
• Kadkhoda J, Tarighatnia A, Tohidkia M, et al. Photothermal therapy-mediated autophagy in breast cancer treatment: progress and trends. Life Sci. 2022;298:120499. doi: 10.1016/j.lfs.2022.120499.
   PubMed Web of Science ®Google Scholar
• Humphry NJ, Wheatley S. Survivin inhibits excessive autophagy in cancer cells but does so independently of its interaction with LC3. Biol Open. 2018;7(10):bio037374.
   Google Scholar
• Wang YF, Zhang W, He KF, et al. Induction of autophagy-dependent cell death by the survivin suppressant YM155 in salivary adenoid cystic carcinoma. Apoptosis. 2014;19(4):748–758. doi: 10.1007/s10495-013-0960-1.
   PubMed Web of Science ®Google Scholar
• Chang YJ, Li LT, Chen HA, et al. Silencing survivin activates autophagy as an alternative survival pathway in HCC cells. Tumour Biol. 2014;35(10):9957–9966. doi: 10.1007/s13277-014-2257-6.
   PubMedGoogle Scholar
• Carmena M, Wheelock M, Funabiki H, et al. The chromosomal passenger complex (CPC): from easy rider to the godfather of mitosis. Nat Rev Mol Cell Biol. 2012;13(12):789–803. doi: 10.1038/nrm3474.
   PubMed Web of Science ®Google Scholar
• Sasai K, Katayama H, Hawke D, et al. Aurora-C interactions with survivin and INCENP reveal shared and distinct features compared with Aurora-B chromosome passenger protein complex. PLOS One. 2016;11(6):e0157305. doi: 10.1371/journal.pone.0157305.
   PubMed Web of Science ®Google Scholar
• Yang D, Welm A, Bishop JM. Cell division and cell survival in the absence of survivin. Proc Natl Acad Sci USA. 2004;101(42):15100–15105. doi: 10.1073/pnas.0406665101.
   PubMed Web of Science ®Google Scholar
• Wheatley SP. The functional repertoire of survivin’s tails. Cell Cycle. 2015;14(2):261–268. doi: 10.4161/15384101.2014.979680.
   PubMed Web of Science ®Google Scholar
• Neophytou CM, Constantinou C, Papageorgis P, et al. D-alpha-tocopheryl polyethylene glycol succinate (TPGS) induces cell cycle arrest and apoptosis selectively in survivin-overexpressing breast cancer cells. Biochem Pharmacol. 2014;89(1):31–42. doi: 10.1016/j.bcp.2014.02.003.
   PubMed Web of Science ®Google Scholar
• Yin W, Chen N, Zhang Y, et al. Survivin nuclear labeling index: a superior biomarker in superficial urothelial carcinoma of human urinary bladder. Mod Pathol. 2006;19(11):1487–1497. doi: 10.1038/modpathol.3800675.
   PubMed Web of Science ®Google Scholar
• Jha K, Shukla M, Pandey M. Survivin expression and targeting in breast cancer. Surg Oncol. 2012;21(2):125–131. doi: 10.1016/j.suronc.2011.01.001.
   PubMed Web of Science ®Google Scholar
• Su L, Wang Y, Xiao M, et al. Up-regulation of survivin in oral squamous cell carcinoma correlates with poor prognosis and chemoresistance. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;110(4):484–491. doi: 10.1016/j.tripleo.2010.04.009.
   PubMed Web of Science ®Google Scholar
• Xie Y, Ma X, Gu L, et al. Prognostic and clinicopathological significance of survivin expression in renal cell carcinoma: a systematic review and meta-analysis. Sci Rep. 2016;6(1):29794. doi: 10.1038/srep29794.
   PubMedGoogle Scholar
• Khan S, Jutzy JM, Valenzuela MM, et al. Plasma-derived exosomal survivin, a plausible biomarker for early detection of prostate cancer. PLOS One. 2012;7(10):e46737. doi: 10.1371/journal.pone.0046737.
   PubMed Web of Science ®Google Scholar
• He C, Liu Z, Ji J, et al. Prognostic value of survivin in patients with non-Hodgkin’s lymphoma: a meta-analysis. Int J Clin Exp Med. 2015;8(4):5847–5854.
   PubMed Web of Science ®Google Scholar
• Li XB, Li SN, Yang ZH, et al. Polymorphisms of survivin and its protein expression are associated with colorectal cancer susceptibility in Chinese population. DNA Cell Biol. 2013;32(5):236–242. doi: 10.1089/dna.2012.1912.
   PubMed Web of Science ®Google Scholar
• Tu SP, Jiang XH, Lin MC, et al. Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res. 2003;63(22):7724–7732.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang W, Wang YF, et al. Dual induction of apoptotic and autophagic cell death by targeting survivin in head neck squamous cell carcinoma. Cell Death Dis. 2015;6(5):e1771–e1771. doi: 10.1038/cddis.2015.139.
   PubMedGoogle Scholar
• Coumar MS, Tsai FY, Kanwar JR, et al. Treat cancers by targeting survivin: just a dream or future reality? Cancer Treat Rev. 2013;39(7):802–811. doi: 10.1016/j.ctrv.2013.02.002.
   PubMed Web of Science ®Google Scholar
• Als AB, Dyrskjøt L, von der Maase H, et al. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res. 2007;13(15 Pt 1):4407–4414. doi: 10.1158/1078-0432.CCR-07-0109.
   PubMed Web of Science ®Google Scholar
• Wang R, Chen DQ, Huang JY, et al. Acquisition of radioresistance in docetaxel-resistant human lung adenocarcinoma cells is linked with dysregulation of miR-451/c-Myc-survivin/rad-51 signaling. Oncotarget. 2014;5(15):6113–6129. doi: 10.18632/oncotarget.2176.
   PubMedGoogle Scholar
• Hinnis AR, Luckett JC, Walker RA. Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients. Br J Cancer. 2007;96(4):639–645. doi: 10.1038/sj.bjc.6603616.
   PubMed Web of Science ®Google Scholar
• Nakagawa Y, Abe S, Kurata M, et al. IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes. Am J Hematol. 2006;81(11):824–831. doi: 10.1002/ajh.20656.
   PubMed Web of Science ®Google Scholar
• Schlette EJ, Medeiros LJ, Goy A, et al. Survivin expression predicts poorer prognosis in anaplastic large-cell lymphoma. J Clin Oncol. 2004;22(9):1682–1688. doi: 10.1200/JCO.2004.10.172.
   PubMed Web of Science ®Google Scholar
• Krishnan A, Mishra D. Antisense oligonucleotides: a unique treatment approach. Indian Pediatr. 2020;57(2):165–171. doi: 10.1007/s13312-020-1736-7.
   PubMed Web of Science ®Google Scholar
• Sardone V, Zhou H, Muntoni F, et al. Antisense oligonucleotide-based therapy for neuromuscular disease. Molecules. 2017;22(4):563. doi: 10.3390/molecules22040563.
   PubMed Web of Science ®Google Scholar
• Tanioka M, Nokihara H, Yamamoto N, et al. Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2011;68(2):505–511. doi: 10.1007/s00280-010-1506-7.
   PubMed Web of Science ®Google Scholar
• Wiechno P, Somer BG, Mellado B, et al. A randomised phase 2 study combining LY2181308 sodium (survivin antisense oligonucleotide) with first-line docetaxel/prednisone in patients with castration-resistant prostate cancer. Eur Urol. 2014;65(3):516–520. doi: 10.1016/j.eururo.2013.10.039.
   PubMed Web of Science ®Google Scholar
• Hansen JB, Fisker N, Westergaard M, et al. SPC3042: a proapoptotic survivin inhibitor. Mol Cancer Ther. 2008;7(9):2736–2745. doi: 10.1158/1535-7163.MCT-08-0161.
   PubMed Web of Science ®Google Scholar
• Sapra P, Wang M, Bandaru R, et al. Down-modulation of survivin expression and inhibition of tumor growth in vivo by EZN-3042, a locked nucleic acid antisense oligonucleotide. Nucleosides Nucleotides Nucleic Acids. 2010;29(2):97–112. doi: 10.1080/15257771003597733.
   PubMed Web of Science ®Google Scholar
• Braasch D, Liu Y, Corey D. Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design. Nucleic Acids Res. 2002;30(23):5160–5167. doi: 10.1093/nar/gkf651.
   PubMed Web of Science ®Google Scholar
• Kurreck J, Wyszko E, Gillen C, et al. Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res. 2002;30(9):1911–1918. doi: 10.1093/nar/30.9.1911.
   PubMed Web of Science ®Google Scholar
• Tolcher AW, Patnaik A, Papadopoulos KP, et al. Abstract LB-409: results of a phase 1, open-label, dose-escalation study evaluating the safety and tolerability of EZN-3042, a survivin mRNA antagonist, administered with or without docetaxel in adult patients with advanced solid tumors or lymphoma. Cancer Research. 2011;71(8_Supplement):LB-409. doi: 10.1158/1538-7445.AM2011-LB-409.
   Google Scholar
• Raetz EA, Morrison D, Romanos-Sirakis E, et al. A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium. J Pediatr Hematol Oncol. 2014;36(6):458–463. doi: 10.1097/MPH.0b013e3182a8f58f.
   PubMed Web of Science ®Google Scholar
• Xiao M, Li W. Recent advances on small-molecule survivin inhibitors. Curr Med Chem. 2015;22(9):1136–1146. doi: 10.2174/0929867322666150114102146.
   PubMed Web of Science ®Google Scholar
• Chiou J, Lee Y, Huang C, et al. Inhibition of Sp1-mediated survivin and MCL1 expression cooperates with SLC35F2 and myeloperoxidase to modulate YM155 cytotoxicity to human leukemia cells. Biochem Pharmacol. 2021;188:114544. doi: 10.1016/j.bcp.2021.114544.
   PubMed Web of Science ®Google Scholar
• Cheng Q, Ling X, Haller A, et al. Suppression of survivin promoter activity by YM155 involves disruption of Sp1-DNA interaction in the survivin core promoter. Int J Biochem Mol Biol. 2012;3(2):179–197.
   PubMedGoogle Scholar
• Nakamura N, Yamauchi T, Hiramoto M, et al. Interleukin enhancer-binding factor 3/NF110 is a target of YM155, a suppressant of survivin. Mol Cell Proteomics. 2012;11(7):M111.013243. doi: 10.1074/mcp.M111.013243.
   PubMed Web of Science ®Google Scholar
• Kumar B, Yadav A, Lang JC, et al. YM155 reverses cisplatin resistance in head and neck cancer by decreasing cytoplasmic survivin levels. Mol Cancer Ther. 2012;11(9):1988–1998. doi: 10.1158/1535-7163.MCT-12-0167.
   PubMed Web of Science ®Google Scholar
• Hou LJ, Huang XX, Xu LN, et al. YM155 enhances docetaxel efficacy in ovarian cancer. Am J Transl Res. 2018;10(3):696–708.
   PubMed Web of Science ®Google Scholar
• Nitta T, Koike H, Miyao T, et al. YM155 reverses statin resistance in renal cancer by reducing expression of survivin. Anticancer Res. 2017;37(1):75–80. doi: 10.21873/anticanres.11291.
   PubMed Web of Science ®Google Scholar
• Chiou J, Lee Y, Huang C, et al. Autophagic HuR mRNA degradation induces survivin and MCL1 downregulation in YM155-treated human leukemia cells. Toxicol Appl Pharmacol. 2020;387:114857. doi: 10.1016/j.taap.2019.114857.
   PubMed Web of Science ®Google Scholar
• Glaros T, Stockwin L, Mullendore M, et al. The “survivin suppressants” NSC 80467 and YM155 induce a DNA damage response. Cancer Chemother Pharmacol. 2012;70(1):207–212. doi: 10.1007/s00280-012-1868-0.
   PubMed Web of Science ®Google Scholar
• Na Y, Yang S, Kim S, et al. YM155 induces EGFR suppression in pancreatic cancer cells. PLOS One. 2012;7(6):e38625. doi: 10.1371/journal.pone.0038625.
   PubMed Web of Science ®Google Scholar
• Grossman S, Ye X, Peereboom D, et al. Phase I study of terameprocol in patients with recurrent high-grade glioma. Neuro Oncol. 2012;14(4):511–517. doi: 10.1093/neuonc/nor230.
   PubMed Web of Science ®Google Scholar
• Ling X, Cao S, Cheng Q, et al. A novel small molecule FL118 that selectively inhibits survivin, mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity. PLOS One. 2012;7(9):e45571. doi: 10.1371/journal.pone.0045571.
   PubMed Web of Science ®Google Scholar
• Ling X, Wu W, Fan C, et al. An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer. J Exp Clin Cancer Res. 2018;37(1):240. doi: 10.1186/s13046-018-0899-8.
   PubMedGoogle Scholar
• Guvenc H, Pavlyukov MS, Joshi K, et al. Impairment of glioma stem cell survival and growth by a novel inhibitor for survivin-Ran protein complex. Clin Cancer Res. 2013;19(3):631–642. doi: 10.1158/1078-0432.CCR-12-0647.
   PubMed Web of Science ®Google Scholar
• Kelly R, Thomas A, Rajan A, et al. A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. Ann Oncol. 2013;24(10):2601–2606. doi: 10.1093/annonc/mdt249.
   PubMed Web of Science ®Google Scholar
• Tolcher A, Quinn D, Ferrari A, et al. A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer. Ann Oncol. 2012;23(4):968–973. doi: 10.1093/annonc/mdr353.
   PubMed Web of Science ®Google Scholar
• Satoh T, Okamoto I, Miyazaki M, et al. Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin Cancer Res. 2009;15(11):3872–3880. doi: 10.1158/1078-0432.CCR-08-1946.
   PubMed Web of Science ®Google Scholar
• Tolcher A, Mita A, Lewis L, et al. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol. 2008;26(32):5198–5203. doi: 10.1200/JCO.2008.17.2064.
   PubMed Web of Science ®Google Scholar
• Shi X, Wang D, Ding K, et al. GDP366, a novel small molecule dual inhibitor of survivin and Op18, induces cell growth inhibition, cellular senescence and mitotic catastrophe in human cancer cells. Cancer Biol Ther. 2010;9(8):640–650. doi: 10.4161/cbt.9.8.11269.
   PubMed Web of Science ®Google Scholar
• Brun S, Markant S, Esparza L, et al. Survivin as a therapeutic target in sonic hedgehog-driven medulloblastoma. Oncogene. 2015;34(29):3770–3779. doi: 10.1038/onc.2014.304.
   PubMed Web of Science ®Google Scholar
• Liu H, Guo S, Roll R, et al. Phi29 pRNA vector for efficient escort of hammerhead ribozyme targeting survivin in multiple cancer cells. Cancer Biol Ther. 2007;6(5):697–704. doi: 10.4161/cbt.6.5.3962.
   PubMed Web of Science ®Google Scholar
• Pennati M, Binda M, De Cesare M, et al. Ribozyme-mediated down-regulation of survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo. Carcinogenesis. 2004;25(7):1129–1136. doi: 10.1093/carcin/bgh107.
   PubMed Web of Science ®Google Scholar
• Fei Q, Zhang H, Fu L, et al. Experimental cancer gene therapy by multiple anti-survivin + hammerhead ribozymes. Acta Biochim Biophys Sin. 2008;40(6):466–477. doi: 10.1111/j.1745-7270.2008.00430.x.
   Google Scholar
• Ling X, Li F. Silencing of antiapoptotic survivin gene by multiple approaches of RNA interference technology. Biotechniques. 2004;36(3):450–460. doi: 10.2144/04363RR01.
   PubMed Web of Science ®Google Scholar
• Wenying Z, Zhaoning J, Zhimin Y, et al. Survivin siRNA inhibits gastric cancer in nude mice. Cell Biochem Biophys. 2012;62(2):337–341. doi: 10.1007/s12013-011-9315-0.
   PubMed Web of Science ®Google Scholar
• Li Q, Zhao J, Liu J, et al. Survivin stable knockdown by siRNA inhibits tumor cell growth and angiogenesis in breast and cervical cancers. Cancer Biol Ther. 2006;5(7):860–866. doi: 10.4161/cbt.5.7.2893.
   PubMed Web of Science ®Google Scholar
• Fu S, Tu Z, Deng L, et al. Induction function of siRNA-mediated survivin gene silencing on nasopharyngeal carcinoma cell apoptosis. Genet Mol Res. 2015;14(1):2537–2545. doi: 10.4238/2015.March.30.12.
   PubMed Web of Science ®Google Scholar
• Xing J, Jia C, Wang Y, et al. Effect of shRNA targeting survivin on ovarian cancer. J Cancer Res Clin Oncol. 2012;138(7):1221–1229. doi: 10.1007/s00432-012-1196-0.
   PubMed Web of Science ®Google Scholar
• Zhang L, Liang H, Cao W, et al. Downregulation of survivin by siRNA inhibits invasion and promotes apoptosis in neuroblastoma SH-SY5Y cells. Braz J Med Biol Res. 2014;47(7):548–553. doi: 10.1590/1414-431x20143459.
   PubMed Web of Science ®Google Scholar
• Wang K, Chen X, Yan F, et al. 5′-triphosphate-siRNA against survivin gene induces interferon production and inhibits proliferation of lung cancer cells in vitro. J Immunother. 2013;36(5):294–304. doi: 10.1097/CJI.0b013e318294183b.
   PubMed Web of Science ®Google Scholar
• Yang C, Li J, Weng H, et al. Adenovirus-mediated transfer of siRNA against survivin enhances the radiosensitivity of human non-small cell lung cancer cells. Cancer Gene Ther. 2010;17(2):120–130. doi: 10.1038/cgt.2009.55.
   PubMed Web of Science ®Google Scholar
• Trabulo S, Cardoso A, Santos-Ferreira T, et al. Survivin silencing as a promising strategy to enhance the sensitivity of cancer cells to chemotherapeutic agents. Mol Pharm. 2011;8(4):1120–1131. doi: 10.1021/mp100426e.
   PubMedGoogle Scholar
• Chen X, Zhang Y, Tang C, et al. Co-delivery of paclitaxel and anti-survivin siRNA via redox-sensitive oligopeptide liposomes for the synergistic treatment of breast cancer and metastasis. Int J Pharm. 2017;529(1–2):102–115. doi: 10.1016/j.ijpharm.2017.06.071.
   PubMed Web of Science ®Google Scholar
• Liu W, Yan H, Qin R, et al. siRNA directed against survivin enhances pancreatic cancer cell gemcitabine chemosensitivity. Dig Dis Sci. 2009;54(1):89–96. doi: 10.1007/s10620-008-0329-4.
   PubMed Web of Science ®Google Scholar
• Li F, Aljahdali I, Ling X. Cancer therapeutics using survivin BIRC5 as a target: what can we do after over two decades of study? J Exp Clin Cancer Res. 2019;38(1):368. doi: 10.1186/s13046-019-1362-1.
   PubMed Web of Science ®Google Scholar
• Shojaei F, Yazdani-Nafchi F, Banitalebi-Dehkordi M, et al. Trace of survivin in cancer. Eur J Cancer Prev. 2019;28(4):365–372. doi: 10.1097/CEJ.0000000000000453.
   PubMed Web of Science ®Google Scholar
• Unsoy G, Gunduz U. Targeted silencing of survivin in cancer cells by siRNA loaded chitosan magnetic nanoparticles. Expert Rev Anticancer Ther. 2016;16(7):789–797. doi: 10.1080/14737140.2016.1184981.
   PubMed Web of Science ®Google Scholar
• Salzano G, Riehle R, Navarro G, et al. Polymeric micelles containing reversibly phospholipid-modified anti-survivin siRNA: a promising strategy to overcome drug resistance in cancer. Cancer Lett. 2014;343(2):224–231. doi: 10.1016/j.canlet.2013.09.037.
   PubMed Web of Science ®Google Scholar
• Yang F, Huang W, Li Y, et al. Anti-tumor effects in mice induced by survivin-targeted siRNA delivered through polysaccharide nanoparticles. Biomaterials. 2013;34(22):5689–5699. doi: 10.1016/j.biomaterials.2013.03.047.
   PubMed Web of Science ®Google Scholar
• Arami S, Rashidi M, Mahdavi M, et al. Synthesis and characterization of FeO-PEG-LAC-chitosan-PEI nanoparticle as a survivin siRNA delivery system. Hum Exp Toxicol. 2017;36(3):227–237. doi: 10.1177/0960327116646618.
   PubMed Web of Science ®Google Scholar
• Ma S, Li X, Ran M, et al. Fabricating nanoparticles co-loaded with survivin siRNA and Pt(IV) prodrug for the treatment of platinum-resistant lung cancer. Int J Pharm. 2021;601:120577. doi: 10.1016/j.ijpharm.2021.120577.
   PubMedGoogle Scholar
• Zhang R, Ma L, Zheng M, et al. Survivin knockdown by short hairpin RNA abrogates the growth of human hepatocellular carcinoma xenografts in nude mice. Cancer Gene Ther. 2010;17(4):275–288. doi: 10.1038/cgt.2009.68.
   PubMed Web of Science ®Google Scholar
• Zhu A, Ren Y, Wang N, et al. Adeno-associated virus mediated gene transfer of shepherdin inhibits gallbladder carcinoma growth in vitro and in vivo. Gene. 2015;572(1):87–94. doi: 10.1016/j.gene.2015.06.080.
   PubMed Web of Science ®Google Scholar
• Weng Y, Fei B, Chi A, et al. Inhibition of gastric cancer cell growth in vivo by overexpression of adeno-associated virus-mediated survivin mutant C84A. Oncol Res. 2013;20(9):411–417. doi: 10.3727/096504013X13657689383094.
   PubMed Web of Science ®Google Scholar
• Fortugno P, Beltrami E, Plescia J, et al. Regulation of survivin function by Hsp90. Proc Natl Acad Sci USA. 2003;100(24):13791–13796. doi: 10.1073/pnas.2434345100.
   PubMed Web of Science ®Google Scholar
• Plescia J, Salz W, Xia F, et al. Rational design of shepherdin, a novel anticancer agent. Cancer Cell. 2005;7(5):457–468. doi: 10.1016/j.ccr.2005.03.035.
   PubMed Web of Science ®Google Scholar
• Wang W, Ji W, Hu H, et al. Survivin promoter-regulated oncolytic adenovirus with Hsp70 gene exerts effective antitumor efficacy in gastric cancer immunotherapy. Oncotarget. 2014;5(1):150–160. doi: 10.18632/oncotarget.1430.
   PubMedGoogle Scholar
• Cheng T, Song Y, Zhang Y, et al. A novel oncolytic adenovirus based on simian adenovirus serotype 24. Oncotarget. 2017;8(16):26871–26885. doi: 10.18632/oncotarget.15845.
   PubMedGoogle Scholar
• Liu R, Mitchell D. Survivin as an immunotherapeutic target for adult and pediatric malignant brain tumors. Cancer Immunol Immunother. 2010;59(2):183–193. doi: 10.1007/s00262-009-0757-9.
   PubMed Web of Science ®Google Scholar
• Jane EP, Premkumar DR, Sutera PA, et al. Survivin inhibitor YM155 induces mitochondrial dysfunction, autophagy, DNA damage and apoptosis in bcl-xL silenced glioma cell lines. Mol Carcinog. 2017;56(4):1251–1265. doi: 10.1002/mc.22587.
   PubMed Web of Science ®Google Scholar
• Li D, He S. MAGE3 and survivin activated dendritic cell immunotherapy for the treatment of non-small cell lung cancer. Oncol Lett. 2018;15(6):8777–8783. doi: 10.3892/ol.2018.8362.
   PubMed Web of Science ®Google Scholar
• Nagaraj S, Pisarev V, Kinarsky L, et al. Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors. J Immunother. 2007;30(2):169–179. doi: 10.1097/01.cji.0000211329.83890.ba.
   PubMed Web of Science ®Google Scholar
• Zhu K, Qin H, Cha S, et al. Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models. Vaccine. 2007;25(46):7955–7961. doi: 10.1016/j.vaccine.2007.08.050.
   PubMed Web of Science ®Google Scholar
• Zhang H, Wang Y, Liu C, et al. DNA and adenovirus tumor vaccine expressing truncated survivin generates specific immune responses and anti-tumor effects in a murine melanoma model. Cancer Immunol Immunother. 2012;61(10):1857–1867. doi: 10.1007/s00262-012-1296-3.
   PubMed Web of Science ®Google Scholar
• Fest S, Huebener N, Bleeke M, et al. Survivin minigene DNA vaccination is effective against neuroblastoma. Int J Cancer. 2009;125(1):104–114. doi: 10.1002/ijc.24291.
   PubMed Web of Science ®Google Scholar
• Ciesielski M, Ahluwalia M, Munich S, et al. Antitumor cytotoxic T-cell response induced by a survivin peptide mimic. Cancer Immunol Immunother. 2010;59(8):1211–1221. doi: 10.1007/s00262-010-0845-x.
   PubMed Web of Science ®Google Scholar
• Burkholz S, Herst C, Carback R, et al. Survivin (BIRC5) peptide vaccine in the 4T1 murine mammary tumor model: a potential neoadjuvant T cell immunotherapy for triple negative breast cancer: a preliminary study. Vaccines. 2023;11(3):644. doi: 10.3390/vaccines11030644.
   Web of Science ®Google Scholar
• Friedrichs B, Siegel S, Andersen M, et al. Survivin-derived peptide epitopes and their role for induction of antitumor immunity in hematological malignancies. Leuk Lymphoma. 2006;47(6):978–985. doi: 10.1080/10428190500464062.
   PubMed Web of Science ®Google Scholar
• Ahluwalia M, Reardon D, Abad A, et al. Phase IIa study of SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma. J Clin Oncol. 2023;41(7):1453–1465. doi: 10.1200/JCO.22.00996.
   PubMed Web of Science ®Google Scholar
• Tanaka T, Kitamura H, Inoue R, et al. Potential survival benefit of anti-apoptosis protein: survivin-derived peptide vaccine with and without interferon alpha therapy for patients with advanced or recurrent urothelial cancer–results from phase I clinical trials. Clin Dev Immunol. 2013;2013:262967–262969. doi: 10.1155/2013/262967.
   PubMedGoogle Scholar
• Shima H, Tsurita G, Wada S, et al. Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA-A24-positive pancreatic adenocarcinoma. Cancer Sci. 2019;110(8):2378–2385. doi: 10.1111/cas.14106.
   PubMed Web of Science ®Google Scholar
• Lennerz V, Gross S, Gallerani E, et al. Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors. Cancer Immunol Immunother. 2014;63(4):381–394. doi: 10.1007/s00262-013-1516-5.
   PubMed Web of Science ®Google Scholar
• Nitschke NJ, Bjoern J, Iversen TZ, et al. Indoleamine 2,3-dioxygenase and survivin peptide vaccine combined with temozolomide in metastatic melanoma. Stem Cell Investig. 2017;4(9):77–77. doi: 10.21037/sci.2017.08.06.
   PubMedGoogle Scholar
• Ge C, Li R, Song H, et al. Phase I clinical trial of a novel autologous modified-DC vaccine in patients with resected NSCLC. BMC Cancer. 2017;17(1):884. doi: 10.1186/s12885-017-3859-3.
   PubMedGoogle Scholar
• Xi H, Wang G, Fu B, et al. Survivin and PSMA loaded dendritic cell vaccine for the treatment of prostate cancer. Biol Pharm Bull. 2015;38(6):827–835. doi: 10.1248/bpb.b14-00518.
   PubMed Web of Science ®Google Scholar
• Sahin U, Oehm P, Derhovanessian E, et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. 2020;585(7823):107–112. doi: 10.1038/s41586-020-2537-9.
   PubMed Web of Science ®Google Scholar
• Leko V, Rosenberg S. Identifying and targeting human tumor antigens for T cell-based immunotherapy of solid tumors. Cancer Cell. 2020;38(4):454–472. doi: 10.1016/j.ccell.2020.07.013.
   PubMed Web of Science ®Google Scholar
• Altieri DC. Targeting survivin in cancer. Cancer Lett. 2013;332(2):225–228. doi: 10.1016/j.canlet.2012.03.005.
   PubMed Web of Science ®Google Scholar
• Fenstermaker RA, Ciesielski MJ, Qiu J, et al. Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma. Cancer Immunol Immunother. 2016;65(11):1339–1352. doi: 10.1007/s00262-016-1890-x.
   PubMed Web of Science ®Google Scholar
• Zhang H, Liu C, Zhang F, et al. MUC1 and survivin combination tumor gene vaccine generates specific immune responses and anti-tumor effects in a murine melanoma model. Vaccine. 2016;34(24):2648–2655. doi: 10.1016/j.vaccine.2016.04.045.
   PubMed Web of Science ®Google Scholar
• Song J, So T, Cheng M, et al. Sustained survivin expression from OX40 costimulatory signals drives T cell clonal expansion. Immunity. 2005;22(5):621–631. doi: 10.1016/j.immuni.2005.03.012.
   PubMed Web of Science ®Google Scholar
• Xing Z, Conway EM, Kang C, et al. Essential role of survivin, an inhibitor of apoptosis protein, in T cell development, maturation, and homeostasis. J Exp Med. 2004;199(1):69–80. doi: 10.1084/jem.20031588.
   PubMed Web of Science ®Google Scholar
• Haque R, Song J, Haque M, et al. c-Myc-Induced survivin is essential for promoting the Notch-Dependent T cell differentiation from hematopoietic stem cells. Genes. 2017;8(3):97. doi: 10.3390/genes8030097.
   Web of Science ®Google Scholar
• Shomali N, Suliman Maashi M, Baradaran B, et al. Dysregulation of survivin-targeting microRNAs in autoimmune diseases: new perspectives for novel therapies. Front Immunol. 2022;13:839945. doi: 10.3389/fimmu.2022.839945.
   PubMed Web of Science ®Google Scholar
• Andersson KM, Brisslert M, Cavallini NF, et al. Survivin co-ordinates formation of follicular T-cells acting in synergy with bcl-6. Oncotarget. 2015;6(24):20043–20057. doi: 10.18632/oncotarget.4994.
   PubMedGoogle Scholar
• Shon HK, Cho KJ, Chung AS. Survivin reduces activation-induced T cell death in G1 phase. Mol Cells. 2003;16(2):147–153. doi: 10.1016/S1016-8478(23)13781-2.
   PubMed Web of Science ®Google Scholar
• Jutzy JM, Khan S, Asuncion-Valenzuela MM, et al. Tumor-released survivin induces a type-2 t cell response and decreases cytotoxic T cell function, in vitro. Cancer Microenviron. 2013;6(1):57–68. doi: 10.1007/s12307-012-0096-9.
   PubMedGoogle Scholar
• Gravina G, Wasén C, Garcia-Bonete MJ, et al. Survivin in autoimmune diseases. Autoimmun Rev. 2017;16(8):845–855. doi: 10.1016/j.autrev.2017.05.016.
   PubMed Web of Science ®Google Scholar
• Wasén C, Turkkila M, Bossios A, et al. Smoking activates cytotoxic CD8(+) T cells and causes survivin release in rheumatoid arthritis. J Autoimmun. 2017;78:101–110. doi: 10.1016/j.jaut.2016.12.009.
   PubMed Web of Science ®Google Scholar
• Colombo M, Raposo G, Théry C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014;30(1):255–289. doi: 10.1146/annurev-cellbio-101512-122326.
   PubMed Web of Science ®Google Scholar
• Khan S, Jutzy JMS, Aspe JR, et al. Survivin is released from cancer cells via exosomes. Apoptosis. 2011;16(1):1–12. doi: 10.1007/s10495-010-0534-4.
   PubMed Web of Science ®Google Scholar
• Aghanejad A, Bonab S, Sepehri M, et al. A review on targeting tumor microenvironment: the main paradigm shift in the mAb-based immunotherapy of solid tumors. Int J Biol Macromol. 2022;207:592–610. doi: 10.1016/j.ijbiomac.2022.03.057.
   PubMed Web of Science ®Google Scholar
• Porporato PE, Filigheddu N, Pedro JMB, et al. Mitochondrial metabolism and cancer. Cell Res. 2018;28(3):265–280. doi: 10.1038/cr.2017.155.
   PubMed Web of Science ®Google Scholar
• Rivadeneira DB, Caino MC, Seo JH, et al. Survivin promotes oxidative phosphorylation, subcellular mitochondrial repositioning, and tumor cell invasion. Sci Signal. 2015;8(389):ra80. doi: 10.1126/scisignal.aab1624.
   PubMed Web of Science ®Google Scholar
• Hagenbuchner J, Kuznetsov AV, Obexer P, et al. BIRC5/survivin enhances aerobic glycolysis and drug resistance by altered regulation of the mitochondrial fusion/fission machinery. Oncogene. 2013;32(40):4748–4757. doi: 10.1038/onc.2012.500.
   PubMed Web of Science ®Google Scholar
• Ju L, Zhang X, Deng Y, et al. Enhanced expression of survivin has distinct roles in adipocyte homeostasis. Cell Death Dis. 2017;8(1):e2533. doi: 10.1038/cddis.2016.439.
   PubMedGoogle Scholar